A. Yadava

发表

Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction

D. Irvine, Heikyung Suh, C. Ockenhouse, 2012, Proceedings of the National Academy of Sciences.

Antigen-Displaying Lipid-Enveloped PLGA Nanoparticles as Delivery Agents for a Plasmodium vivax Malaria Vaccine

D. Irvine, Heikyung Suh, C. Ockenhouse, 2012, PloS one.

Effect of Codon Optimization on Expression Levels of a Functionally Folded Malaria Vaccine Candidate in Prokaryotic and Eukaryotic Expression Systems

C. Ockenhouse, A. Yadava, 2003, Infection and Immunity.

Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax.

C. Ockenhouse, M. Washington, A. Yadava, 2009, Vaccine.

A Novel Chimeric Plasmodium vivax Circumsporozoite Protein Induces Biologically Functional Antibodies That Recognize both VK210 and VK247 Sporozoites

J. Sattabongkot, C. Ockenhouse, Sanjai Kumar, 2006, Infection and Immunity.

Asymptomatic Plasmodium vivax infections induce robust IgG responses to multiple blood-stage proteins in a low-transmission region of western Thailand

J. Rayner, R. Longley, M. White, 2017, Malaria Journal.

Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice.

S. Bertholet, S. Reed, S. Nurmukhambetova, 2012, Vaccine.

Immunogenicity and Efficacy in Aotus Monkeys of Four Recombinant Plasmodium falciparum Vaccines in Multiple Adjuvant Formulations Based on the 19-Kilodalton C Terminus of Merozoite Surface Protein 1

M. Blackman, D. Kaslow, Sanjai Kumar, 2000, Infection and Immunity.

Particle-based platforms for malaria vaccines.

G. Jennings, Yimin Wu, D. Narum, 2015, Vaccine.

Evidence for the transmission of Plasmodium vivax in the Republic of the Congo, West Central Africa.

C. Coban, R. Carter, T. Tsuboi, 2009, The Journal of infectious diseases.

An immunodominant 30-kDa antigen of a candidate anti-leprosy vaccine,Mycobacterium w, shares T and B cell determinants withM. leprae andM. tuberculosis

A. Yadava, R. Mukherjee, 1993, Medical Microbiology and Immunology.

T‐Cell Responses to Fractionated Antigens of Mycobacterium w, a Candidate Anti‐Leprosy Vaccine, in Leprosy Patients

G. P. Talwar, A. Yadava, N. Suresh, 1991, Scandinavian journal of immunology.

Identification of highly-protective combinations of Plasmodium vivax recombinant proteins for vaccine development

J. Rayner, M. Galinski, A. Cowman, 2017, eLife.

Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy

Joshua D. Hartzell, W. Ballou, Joe D. Cohen, 2016, PLoS neglected tropical diseases.

Protective Efficacy of a Plasmodium vivax Circumsporozoite Protein-Based Vaccine in Aotus nancymaae Is Associated with Antibodies to the Repeat Region

J. Barnwell, C. Ockenhouse, W. Collins, 2014, PLoS neglected tropical diseases.

Genome-Wide Expression Profiling in Malaria Infection Reveals Transcriptional Changes Associated with Lethal and Nonlethal Outcomes

C. Ockenhouse, Sanjai Kumar, K. Schaecher, 2005, Infection and Immunity.

Immunogenicity and In Vivo Efficacy of Recombinant Plasmodium falciparum Merozoite Surface Protein-1 in Aotus Monkeys

D. Kaslow, Sanjai Kumar, M. Ohl, 1995, Molecular medicine.

Positive rK39 serologic assay results in US servicemen with cutaneous leishmaniasis.

Joshua D. Hartzell, G. Wortmann, R. Howard, 2008, The American journal of tropical medicine and hygiene.

Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.

W. Mccarthy, C. Ockenhouse, J. Bennett, 2013, The New England journal of medicine.

Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques.

Joe D. Cohen, J. Sattabongkot, C. Ockenhouse, 2013, Vaccine.

Development of a Chimeric Plasmodium berghei Strain Expressing the Repeat Region of the P. vivax Circumsporozoite Protein for In Vivo Evaluation of Vaccine Efficacy

C. Ockenhouse, E. Angov, F. Zavala, 2013, Infection and Immunity.

Protein disulfide isomerase assisted protein folding in malaria parasites.

J. K. Moch, J. Haynes, H. Nakhasi, 2006, International journal for parasitology.

Mosquito Bite-Induced Controlled Human Malaria Infection with Plasmodium vivax or P. falciparum Generates Immune Responses to Homologous and Heterologous Preerythrocytic and Erythrocytic Antigens

D. Chattopadhyay, E. Bergmann-Leitner, E. Angov, 2018, Infection and Immunity.

Title Evidence for the transmission of Plasmodium vivax in the Republic of theCongo , West Central Africa . Author ( s )

C. Coban, R. Carter, T. Tsuboi, 2017 .

Trafficking of Plasmodium chabaudi adami-infected erythrocytes within the mouse spleen.

G. Milon, J. Dvorak, L. Miller, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Effect of Codon Optimization on Expression Levels of a Functionally Folded Malaria Vaccine Candidate in Prokaryotic and Eukaryotic Expression Systems

C. Ockenhouse, A. Yadava, 2003, Infection and Immunity.

Cross-species immunity following immunization with a circumsporozoite protein-based vaccine for malaria.

S. Nurmukhambetova, A. Pichugin, A. Yadava, 2012, The Journal of infectious diseases.

Evaluation of the Safety and Immunogenicity in Rhesus Monkeys of a Recombinant Malaria Vaccine for Plasmodium vivax with a Synthetic Toll-Like Receptor 4 Agonist Formulated in an Emulsion

S. Bertholet, S. Reed, T. Vedvick, 2011, Infection and Immunity.

Evaluation of the safety and immunogenicity in rhesus monkeys of a 1 recombinant malaria vaccine for Plasmodium vivax with a synthetic 2 TLR 4 agonist formulated in an emulsion

S. Bertholet, S. Reed, S. Nurmukhambetova, 2011 .

The challenges of Plasmodium vivax human malaria infection models for vaccine development

W. Roobsoong, S. Draper, A. Minassian, 2023, Frontiers in Immunology.

Cross-species immunity following immunization with a circumsporozoite protein-based vaccine for malaria.

S. Nurmukhambetova, A. Pichugin, A. Yadava, 2012, The Journal of infectious diseases.

Rationale for Further Development of a Vaccine Based on the Circumsporozoite Protein of Plasmodium vivax

N. Waters, A. Yadava, 2017, PLoS neglected tropical diseases.